Teva Pharmaceutical Industries(NYSE) TEVA

Teva helps people stay healthy by making and selling many different types of medicines. It makes cheaper versions of common drugs and creates new treatments for brain and breathing problems. Patients around the world use these products to manage pain, migraines, and long-term illnesses.

What is in the Medicine Cabinet?

• Generic Medicines: Copies of brand-name drugs that are identical in use and safety; offered in forms like tablets, capsules, and inhalants.
• Innovative Medicines: Patented treatments for complex conditions such as Huntington’s disease, migraine prevention, and schizophrenia.
• Biosimilars: Highly similar versions of large, complex biologic drugs used for treating cancer and autoimmune diseases.
• Anda Distribution: Wholesale service that ships generic and brand-name drugs to pharmacies and hospitals across the United States.
• API Production: Development and sale of active pharmaceutical ingredients, which are the main chemical parts of any medicine.

Recent Growth and New Directions

• Entered a strategic partnership with Samsung Bioepis in January 2025 to sell a new biosimilar for rare blood and nerve disorders in the U.S.
• Signed a collaboration with Formycon in January 2025 to bring a treatment for severe eye diseases to European and Israeli markets.
• Expanded the innovative pipeline by filing a New Drug Application for a long-acting schizophrenia treatment in December 2025.
• Initiated Phase 3 medical studies for a new bowel disease treatment in October 2025 through a partnership with Sanofi.

What Makes This Business Stand Out

Teva operates a massive global network with approximately 34,000 employees working across 57 different markets to deliver essential healthcare. The company maintains a competitive edge by combining its leadership in high-volume generic drugs with a specialized focus on complex innovative medicines for the central nervous system.

The Financial Scorecard

• Revenue reached $4.7 billion in Q4 2025, an 11.4% increase from Q4 2024.
• Gross profit grew to $2.7 billion in Q4 2025, up 25.3% from the same period in 2024.
• Net income rose to $480 million in Q4 2025, compared to a loss of $217 million in Q4 2024.
• Free cash flow hit $1 billion in Q4 2025, an increase of 127.8% year-over-year.

The Bottom Line

Teva has successfully shifted its focus toward high-value innovative medicines while maintaining its foundation in the global generic drug market. This transition supports a leaner business model focused on long-term growth and debt reduction.